P eripheral arterial disease is caused by atherosclerosis of peripheral arteries. Its progression leads to critical limb ischemia, a condition with estimated 25% mortality in the first year. 1 This mortality rate is even higher in patients requiring amputation. 1 Despite the new advances in revascularization therapies, treatment is not effective in most cases. 2 Therefore, angioarteriogenic strategies aimed at restoring blood flow in the ischemic limb through cell and gene therapy have emerged as possible alternatives.
Previous studies have shown that adipose stromal cells (ASCs) have a marked angiogenic potential in vivo, improving tissue perfusion in animal models of hindlimb ischemia mainly through the release of multiple angiogenesis-related growth factors and cytokines. [3] [4] [5] Moreover, recent phase I trials in patients with critical limb ischemia showed that angiogenic treatments with autologous ASCs are safe and potentially beneficial. [6] [7] [8] On the other hand, we have shown that direct intramuscular injection of a plasmid encoding human vascular endothelial growth factor 165 (VEGF 165 ) in rabbits with hindlimb ischemia increases microvascular density. However, protection against ischemic muscle lesions in the affected limb was afforded only if the treatment was repeated, the reason being that VEGF expression, and hence the vasculogenic stimulus, decayed steeply after the seventh day post injection. 9 Therefore, we hypothesized that genetically modifying ASCs to overexpress human VEGF 165 would enhance the vasculogenic potential of ASCs, not only by increasing the paracrine angiogenic effect of ASCs but also by attenuating the decay of VEGF expression in the target tissue. In turn, these effects would protect the ischemic muscle against necrotic lesions to a significantly larger extent than nontransfected ASCs.
Results

VEGF-Overexpressing ASCs Retention in the Target Tissue Is High at 7 Days and Low at 30 Days After Implantation
ASCs taken from the abdominal fat were positive for the anti-CD44 antibody, mildly positive for the anti-CD90 and anti-CD105 antibodies, and negative for anti-CD45 and anti-CD34 antibodies. ASCs were able to differentiate into osteocyte and chondrocyte lineages ( Figure I in the online-only Data Supplement).
Before performing the main protocol, we aimed at studying retention and viability of the study cells in the target tissue. To this end, ASCs from male donors were transfected with a plasmid encoding human VEGF 165 (ASCs-VEGF), stained with a fluorescent dye and injected in ischemic left adductor and quadriceps muscles of female recipients. Fluorescence microscopy revealed that injected ASCs-VEGF were present in considerable amount at 7 days and scarcely at 30 days ( Figure 1A and 1B). Assessment of the sex-determining region Y gene (SRY) of the male donor ASCs followed the same pattern, namely high amplification at 7 days (616.1±240.1-fold increase with regard to control) and low at 30 days (12.5±14.9; Figure 1C ).
Transgene Expression Decreases Over Time but Is Still Detectable at 30 Days After Treatment
Transgene expression in the target muscles was assessed by reverse transcriptase-polymerase chain reaction ( Figure 1D ). Human VEGF mRNA was maximum at 7 days (11 160.8±818.9-fold increase versus control) and decreased at 14 (10.7±13.1), 21 (2.8±1.3), and 30 (2.2±1.7) days. Immunohistochemistry against human VEGF in injected muscles of ASCs-VEGF-treated rabbits showed VEGF protein expression at 7 and 30 days post injection. Slices from a placebo-treated rabbit at the same time points are also depicted ( Figure 1E ).
VEGF-Transfected ASCs and Nontransfected ASCs Induce Comparable Improvements in Ischemic Limb Hemodynamics
Rabbits undergoing full extirpation of the left superficial femoral artery and ligature of the deep left femoral artery were injected in the target muscles with ASCs (n=10), ASCs-VEGF (n=10), or vehicle (n=10). One and 30 days after surgery, we performed a Doppler echo on both hind limbs to assess preand post-treatment hemodynamic variables (Figure 2 ).
Peak systolic flow velocity (PSV) increased significantly in ASCs-VEGF group from 11.1±3.3 cm/s (mean±SD) to 23.4±19 cm/s at 30 days (P<0.05). In the ASCs and placebo groups, PSV showed a tendency to increase but no statistically significant differences were found ( Figure 2A The blood pressure ratio increased significantly in the ASCs group (0.29±0.27-0.63±0.23; P<0.05) and showed a strong tendency to increase (yet not statistically significant) in the ASCs-VEGF group (from 0.26±0.14 to 0.59±0.28; P=NS). No significant change in blood pressure ratio was observed in the placebo group (from 0.39±0.22 to 0.54±0.27; P=NS). Overall, these results show that both treated groups exhibited comparable over time improvements in ischemic limb hemodynamics.
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ASCs and VEGF-Transfected ASCs Afford Equal Protection Against Ischemic Muscle Damage
Samples obtained from the ischemic adductor and quadriceps were assessed for ischemic lesions under light microscopy. Three types of ischemic muscle lesions were observed: (1) decreased density of fibers plus adipose tissue replacement; (2) atrophy and lipomatosis; and (3) areas of necrosis, fiber replacement with scar tissue, and myositis.
Independent from the type of lesion, samples were divided into normal and pathological and expressed as percentage of the total samples. The percentage of samples displaying pathological muscle lesions was almost equally lower in ASCs-VEGF (19%) and ASCs (17%) when compared with placebo (40%; P<0.05 versus ASCs and ASCs-VEGF; Fisher test; Figure 5 ).
Discussion
Our results show that VEGF-overexpressing ASCs induced a higher density of angiographically visible collaterals and capillaries. However, their effect on protection against ischemic muscle lesions was equal to that afforded by nontransfected ASCs. Both treatments increased arteriolar density to a similar extent, suggesting that tissue protection depended principally on the development of a network of smooth muscle-walled microvessels. ASCs-induced arteriolar proliferation was to be expected, on account that they secrete several cytokines and growth factors, other than VEGF, involved in vasculogenesis, such as hepatocyte growth factor, transforming growth factor-β, fibroblast growth factor-2, insulin like growth factor-3, and stromal cell-derived factor-1.
3,10,11 Given the well-known angiogenic effect of VEGF, it is also sound that the group treated with ASCs that overexpressed VEGF exhibited higher capillary density.
Given that in terms of capillary and collateral densities, the differences between ASCs-VEGF and ASCs did not achieve significance, it is reasonable to assume that these neovessels participated in the protective effect. However, the arteriolar density results underscore the importance of arteriolar neoformation in treatments directed to restore muscle perfusion and limit ischemic damage, as has been previously claimed. 12 Besides being more stable and less prone to regress than neovessels formed by only endothelium, arterioles respond to the physiological stimuli regulating vascular tone and thus tissue perfusion. Capillaries, however, permit the exchange of gases and nutrients between blood and cells, but their blood flow critically depends on an arteriolar network adequate in size and function. It is, therefore, not surprising that both treatments exerted similar protection against ischemic muscle lesions.
As was the case with capillaries, the higher collateral vessel density observed in the ASCs-VEGF group made no difference in terms of muscle protection when compared with the nontransfected ASCs group. Moreover, the influence of a higher number of angiographically visible collaterals on the diverse variables assessed by Doppler echo was subtle. In effect, in the ASCs-VEGF group, the only parameter in which the posttreatment improvements achieved statistical significance was PSV. The ratio of PSV of ischemic to nonischemic limb, as well as the PSV/diastolic velocity index and the resistance index, improved similarly in both treated group. Furthermore, the post-treatment improvement observed in blood pressure ratio achieved significance in the group treated with nontransfected ASCs. Taken together, these results help concluding that tissue salvage depended principally on arteriolar proliferation.
Previous studies have shown that the neovessels induced by angiogenic treatments lack stability and tend to regress in the absence of the mitogenic stimulus. 13, 14 According to Dor et al, 15 in the case of VEGF, the critical time for the neovessels to become refractory to VEGF withdrawal is 4 weeks. In our rabbits, we tracked the injected VEGF-transfected ASCs by visualization of stained cells and detection of the Y gene of male donor cells in female recipients and found that cell retention and viability were low but still detectable at 1 month after injection. Human VEGF expression followed a similar pattern, decreasing over time but lasting (although in low level) until the end of follow-up. These results indicate that a certain degree of paracrine mitogenic stimulation persisted beyond the period considered necessary for the stabilization of the neovascular network. In effect, human VEGF protein was readily observed in injected muscles of ASCs-VEGF-treated rabbits at 30 days after treatment. However, in terms of muscle protection, our results did not support the hypothesis that VEGF overexpression would enhance the benefits of ASCs implant in ischemic limbs. In this regard, our results differ from those of Shevchenko et al, 16 who implanted 5×10 5 human ASCs transduced with an adenoassociated virus encoding VEGF 165 in nude mice with hindlimb ischemia. These authors found significantly higher arteriolar density and significantly lower muscle damage in mice treated with transduced ASCs. However, the results are not strictly comparable, not only because of differences in the donor cells (human versus cunine) and the host species (nude mouse versus wild-type rabbit) but also because of the vector used. The authors do not report the transduction efficiency reached with the adenoassociated virus, but it is reasonable to assume that it was high. In our experiments, the maximum transfection efficiency achieved after optimizing the relationship between transfection reagent and DNA mass was 20%, similar to the value reported by Gheisari et al 17 for rat bone marrow mesenchymal stromal cells. Therefore, the amount of VEGF-overexpressing ASCs injected was ≈2 million in our rabbits and 5×10 5 in Shevchenko's mice. Considering the size of both animals, the concentration of VEGF-overexpressing cells in the target tissue was ≥5-fold higher in their mice, a fact that may account for the differences observed.
In conclusion, allogeneic ASCs overexpressing human VEGF 165 increase capillary density and angiographically visible collaterals in a rabbit model of hindlimb ischemia. However, they afford equal protection against ischemic muscle lesions than nontransfected ASCs, because of the fact that both treatments increase arteriolar density to a similar extent. To enhance their regenerative potential, stem cells are usually modified to overexpress angiogenic growth factors. In rabbits with critical limb ischemia, we show that allogeneic adipose stromal cells modified to overexpress human vascular endothelial growth factor do not afford greater protection against ischemic muscle damage than nonmodified cells, despite the fact that modified cells induce larger capillary growth and angiographically visible collaterals than nontransfected cells. The reason for modified and nonmodified adipose stromal cells exhibiting similar anti-ischemic protective effect seems to be their equal ability to induce arteriolar growth, highlighting the pivotal role of arteriolar neoformation for tissue salvage in critical limb ischemia.
Significance
